In this issue of Blood, O'Brien and colleagues 1 demonstrate impaired growth of circulating red-cell progenitor cells ex vivo from patients with Diamond-Blackfan anemia (DBA) with ribosomal protein (RP) or GATA1 mutations. Distinct transcriptional profiles in erythroid cells from patients with RP and GATA1 mutations indicate potential mechanisms underlying dysregulation of translation.
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BA is an inherited bone marrow failure syndrome that is characterized by defects in erythropoiesis, congenital abnormalities, and predisposition to cancer. Treatment of the anemia relies on steroids and red-cell transfusions. 2 In 1999, the first ribosomal protein subunit, RPS19, was identified in association with DBA. 3 Since then, as many as 72% of patients with DBA have been found to have heterozygous pathogenic mutations in RP genes. 4 Another mutation more recently identified through whole-exome sequencing is the erythroidspecific transcription factor GATA1, resulting in altered translation. 5, 6 The remaining patients with DBA do not have any identifiable mutations. Several model systems have been developed to recapitulate the phenotype of DBA, including mice, zebrafish, and inducible pluripotent stem cells. [7] [8] [9] Heterozygous mice with RPS19 mutations do not have an anemia phenotype, whereas RPS19 knockout in mice is lethal. Inducible pluripotent stem cells can be difficult to differentiate to the erythroid lineage. Zebrafish provide insights into development, but there are limited reagents available to study specific pathways. Lymphocyte cell lines from patients with DBA are Epstein-Barr virus transformed, which could confound results of mechanistic experiments and make interpretation of results difficult. Obtaining bone marrow from patients with DBA can be cumbersome and requires anesthesia for a potentially unnecessary procedure, because the diagnosis can be made through gene testing of peripheral blood cells and assaying erythrocyte adenine deaminase activity.
One of the challenges in studying the molecular pathogenesis of DBA has been the limited numbers of cells obtained from bone marrow of patients with DBA. This paper describes a 2-phase ex vivo culture method to characterize erythroid differentiation, transcriptional profiles, and steroid responses of 11 patients with DBA with various RP and GATA1 mutations.
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The caveats of these studies are whether the samples are being analyzed at the same time points during erythroid differentiation and whether the populations are homogeneous. The key factor to elucidating the specific events mediating bone marrow failure will be to fill the gaps in knowledge of how the changes in gene expression are linked to translation. The identification of key steps in this regulation will lead to potential avenues to treat DBA.
